Dalvance dalbavancin regulatory update

FDA's Anti-Infective Drugs Advisory Committee voted 12-0 in favor of approval of Dalvance dalbavancin from Durata to treat acute bacterial skin and skin structure infections (ABSSSI). Durata is seekin...